SuperworthClover Health Investments CLOV
- Market cap
- $2.4B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.5B
- +54% on a year ago
- Net margin
- −0.7%
- Free cash flow yield
- 3.0%
Clover Health Investments trades at 1.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.5B over the last twelve months, up 54% on a year earlier with a −1% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $306M−64% | $312.4M−65% | $346.9M+8% | $356.3M+11% | $331M+8% | $337M+8% | $462.3M+33% | $477.6M+34% | $496.6M+50% | $487.7M+45% | $749.2M+62% | $743.2M+56% | |
| SG&A | $41M−14% | $42.7M−23% | $44.6M−23% | $44.4M+7% | $35.2M−14% | $52.3M+22% | $50.7M+14% | $48.5M+9% | $49M+39% | $66.2M+27% | $74.6M+47% | $70.3M+45% |
| −$33.6M−55% | −$63.1M−41% | −$22.7M−72% | $7.2M | −$8.8M−74% | −$21.4M−66% | −$1.3M−94% | −$10.6M | −$24.4M+178% | −$49.3M+130% | $27.3M | $28M | |
| Interest expense | $0 | $0 | n/a | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$41.5M−45% | −$70.5M−16% | −$19.2M−74% | $7.4M | −$9.2M−78% | −$22.1M−69% | −$1.3M−93% | −$10.6M | −$24.4M+166% | −$49.3M+123% | $27.3M | $28M |
| −$0.07−56% | −$0.15−17% | −$0.05−71% | $0.01 | −$0.02−71% | −$0.04−73% | $0.00 | −$0.02 | −$0.05+150% | −$0.10+150% | $0.05 | $0.05 | |
| 480.8M+1% | 485.9M+2% | 486.4M+2% | 495.2M+3% | 490.2M+2% | 494.5M+2% | 497.1M+2% | 509M+3% | 512.7M+5% | 517.2M+5% | 532.5M+7% | 545.4M+7% |
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x1.228). 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Healthcare Plans nearest Clover Health Investments' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CLOVClover Health Investments | $2.4B | n/m | n/a | 1.0× | +54% | −0.7% | |
| ALHCAlignment Healthcare | $1.7B | 42.4× | 124× | 0.4× | +37% | 0.9% | |
| TRUPTrupanion | $1.3B | 55.3× | 60.0× | 0.8× | +12% | 1.5% | |
| OSCROscar Health | $9.6B | 22.3× | 47.9× | 0.6× | +43% | 3.6% | |
| Peer median | $1.7B | 42.4× | 60.0× | 0.6× | +37% | 1.5% |
More on Clover Health Investments
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 11Health insurers with the fastest revenue growth
- #10of 11Health insurers with the highest profit margins
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .